Program
Please Note: All session times for the AACR Virtual Meeting: Clonal Hematopoiesis are U.S. Eastern Standard Time (EST).
Wednesday, August 18, 2021
Thursday, August 19, 2021
- Session 3: Clonal Hematopoiesis and Non-Blood Cancer Consequences
- Session 4: Population Level Studies of Clonal Hematopoiesis
- Panel Discussion: Clonal Hematopoiesis: How Do We Design Clinical Trials and Approve Drugs?
WEDNESDAY, AUGUST 18, 2021
Sessions 1 and 2: DTA and non-dta Mutations
Moderators: MARIA E. (KEN) FIGUEROA, UNIVERSITY OF MIAMI, MIAMI, FLORIDA AND RAVI MAJETI, STANFORD UNIVERSITY, STANFORD, CALIFORNIA
10 a.m.-1 p.m.
Session 1 and 2 Introduction
Ravi Majeti
SESSION 1: DTA MUTATIONS
10:10-11:10 a.m.
Dnmt3A mutations in clonal hematopoiesis
Jennifer Trowbridge, The Jackson Laboratory, Bar Harbor, Maine
TET2 mutations, inflammation-induced plasticity, and myeloid transformation
Iannis Aifantis, New York University Langone Medical Center, New York, New York
ASXL1 mutations in clonal hematopoiesis
Ravi Majeti, Stanford University, Stanford, California
Break
11:10-11:25 a.m.
Session 2: Non-DTA Mutations
11:25 a.m.-12:05 p.m.
Mechanisms of clonal competition in the context of PPM1D mutations
Margaret A. Goodell, Baylor College of Medicine, Houston, Texas
Spliceosome mutations in clonal hematopoiesis
Esther Obeng, St. Jude Children’s Research Hospital, Memphis, Tennessee
DTA vs. Non-DTA Panel Discussion
12:05-1 P.M.
Moderators: MARIA E. (KEN) FIGUEROA, UNIVERSITY OF MIAMI, MIAMI, FLORIDA AND RAVI MAJETI, STANFORD UNIVERSITY, STANFORD, CALIFORNIA
Panelists
Jennifer Trowbridge
Iannis Aifantis
Margaret A. Goodell
Esther Obeng
THURSDAY, AUGUST 19, 2021
Session 3: Clonal Hematopoiesis and Non-Blood Cancer Consequences
Moderator: Benjamin L. Ebert, Dana-Farber Cancer Institute, Boston, Massachusetts
10-11:25 a.m.
Session Introduction
Benjamin L. Ebert
Clonal hematopoiesis and risk of cardiovascular diseases
Siddhartha Jaiswal, Stanford University, Stanford, California
Clonal hematopoiesis and infection risk: Correlations and complications
Kelly L. Bolton, Washington University of St. Louis, St. Louis, Missouri
Deciphering and targeting clonal hematopoiesis
Ross L. Levine, Memorial Sloan Kettering Cancer Center, New York, New York
Panel Discussion
Siddhartha Jaiswal
Kelly Bolton
Ross L. Levine
Break
11:25-11:40 a.m.
Session 4: Population-Level Studies of Clonal Hematopoiesis
Moderator: Maria E. (Ken) Figueroa, University of Miami, Miami, Florida
11:40 a.m.-1 p.m.
Session Introduction
Maria E. (Ken) Figueroa
CHIP in elderly twins: Concordance, discordance, survival, and epigenetics
Kirsten Grønbæk, Rigshospitalet and BRIC, University of Copenhagen, Copenhagen, Denmark
Population studies in clonal hematopoiesis: Hematologic malignancies
Pinkal Desai, Weill Cornell Medical College, New York, New York
Clonal hematopoiesis and risk for cardiovascular disease: Insights from population-based studies
Pradeep Natarajan, Massachusetts General Hospital, Boston, MA
Panel Discussion
Pinkal Desai
Pradeep Natarajan
Break
1-1:30 p.m.
Panel Discussion
Clonal Hematopoiesis: How Do We Design Clinical Trials and Approve Drugs?
Moderators: Ravi Majeti, Stanford University, Stanford, California, and Maria E. (Ken) Figueroa, University of Miami, Miami, Florida
Panelists
Kelly L. Bolton, Washington University of St. Louis, St. Louis, Missouri
Benjamin L. Ebert, Dana-Farber Cancer Institute, Boston, Massachusetts
David Steensma, Novartis, Cambridge, Massachusetts